Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold - 2Netflix is releasing a documentary on Elizabeth Smart. What to know about her kidnapping, rescue and where she is now.
- 3Understanding Various Sorts of Financial balances: An Extensive Outline
- 43 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- 5Figure out how to Put resources into Lab Precious stones: A Novice's Aide
- Medicine doesn’t just have ‘conscientious objectors’ − there are ‘conscientious providers,’ too
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- Vote In favor of Your Favored Treat
- Ancient eggshells shed new light on crocodiles that hunted prey from trees
- Dominating the Art of Composing: Creator Bits of knowledge
- Iran war upends aviation strategies
- Scaling New Levels: Rock Climbing Spots On the planet
- 4 well known subjects in school
- Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
